The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Claims

8 · 1 independent · depth 4

8 granted claims

›1.independentAn isolated polynucleotide encoding a cross-reactive monoclonal antibody or antigen-binding fragment thereof which specifically binds to both IL-17A (…+7

›2.↳ 1The isolated polynucleotide of claim 1, wherein the monoclonal antibody is a humanized antibody comprising the CDRs of the antibody produced by the hy…d2+3

›6.↳ 1An expression vector comprising the following operably linked elements:na) a transcription promoter;b) a DNA segment comprising the polynucleotide of …d2+2

Classifications

10 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C12N15/09
C12N15/13

USPC · US Patent Classification

435/69.6530/387.1435/325435/320.1530/351536/23.53530/808435/252.3

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

1.0 y

372 days filing → grant

Office actions

non-final + final

Responses

no RCE

Interviews

examiner interview summaries

Examiner

Dong Jiang

art unit 1646 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 134 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

2 priority documents

Priority

10 Mar 2006

earliest claimed

›Priority documents — 2

Type	Document	Date
provisional	US 60781121	10 Mar 2006
related publication	US 20120329093 A1	27 Dec 2012

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.